EUVIMEDEUVIMED entdecken
Crossref

Balfaxar: Another Four-Factor PCC for Warfarin Reversal

The Medical Letter on Drugs and Therapeutics · 2024

DOI: 10.58347/tml.2024.1696d ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2024. Hauptthemen laut MEDLINE: Warfarin, Hemorrhage.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Balfaxar (Octapharma), a human plasma-derived four-factor prothrombin complex concentrate (PCC), has been approved by the FDA for rapid reversal of warfarin anticoagulation in adults who require an urgent surgical/invasive procedure. It is the second four-factor PCC to become available in the US; Kcentra, which has been available since 2013, is approved for the same indication and for urgent reversal of warfarin anticoagulation in adults with acute major bleeding. Balfaxar is marketed in Canada and Europe as Octaplex.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

WarfarinHemorrhageHumansAnticoagulantsBlood Coagulation FactorsRecombinant ProteinsFactor Xa Inhibitors

Stichwörter der Autor:innen

AndexxaBalfaxarDOACKcentraOctaplexPradaxaPraxbindSavyasaadverse effectsandexanet alfadosageedoxabanefficacyidarucizumabprothrombin complex concentrates

Substanzen

WarfarinAnticoagulantsBlood Coagulation FactorsRecombinant ProteinsFactor Xa Inhibitors

Zitieren

APA

(2024). Balfaxar: Another Four-Factor PCC for Warfarin Reversal. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1696d

Vancouver

Balfaxar: Another Four-Factor PCC for Warfarin Reversal. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1696d

BibTeX
@article{euvimed2024,
  title = {Balfaxar: Another Four-Factor PCC for Warfarin Reversal},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2024},
  doi = {10.58347/tml.2024.1696d}
}
Kostenlos starten →